Long-term follow-up of asymptomatic Brugada patients with inducible ventricular fibrillation under hydroquinidine

Europace

Volumn 16, Issue 4, 2014, Pages 572-577

  Bouzeman, Abdeslam ^a   Traulle, Sarah ^b   Messali, Anne ^a   Extramiana, Fabrice ^a,c   Denjoy, Isabelle ^a,d   Narayanan, Kumar ^e   Marijon, Eloi ^e   Hermida, Jean Sylvain ^b   Leenhardt, Antoine ^a,c  

^a BICHAT HOSPITAL   (France)

^b AMIENS UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

Author keywords

Brugada syndrome; Cardioverter defibrillator; Hydroquinidine; Primary prevention; Programmed ventricular stimulation; Sudden cardiac death

Indexed keywords

AJMALINE; DIHYDROQUINIDINE; FLECAINIDE; ANTIARRHYTHMIC AGENT; QUINIDINE;

ADULT; ARTICLE; ASYMPTOMATIC DISEASE; BRUGADA SYNDROME; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; FAINTNESS; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HEART STIMULATION; HEART VENTRICLE FIBRILLATION; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; INAPPROPRIATE SHOCK; LEAD FRACTURE; LONG TERM CARE; MALE; MEDICAL DEVICE COMPLICATION; MULTICENTER STUDY; PHOTOSENSITIVITY; PRIORITY JOURNAL; PROGRAMMED VENTRICULAR STIMULATION; PROSPECTIVE STUDY; QT INTERVAL; SUPRAVENTRICULAR TACHYCARDIA; TWIDDLER SYNDROME; ANALOGS AND DERIVATIVES; CARDIOVERSION; CLINICAL TRIAL; DEVICES; FRANCE; HEART FUNCTION TEST; MIDDLE AGED; PATHOPHYSIOLOGY; TIME; TREATMENT OUTCOME; VENTRICULAR FIBRILLATION;

ADULT; ANTI-ARRHYTHMIA AGENTS; ASYMPTOMATIC DISEASES; BRUGADA SYNDROME; DEFIBRILLATORS, IMPLANTABLE; ELECTRIC COUNTERSHOCK; ELECTROPHYSIOLOGIC TECHNIQUES, CARDIAC; FEMALE; FOLLOW-UP STUDIES; FRANCE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUINIDINE; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR FIBRILLATION;

EID: 84898851547     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eut279     Document Type: Article

References (27)

1. Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: A distinct clinical and electrocardiographic syndrome: A multicenter report. J Am Coll Cardiol 1992;20:1391-6
2. Antzelevitch C, Brugada P, Borggrefe M, Brugada J, Brugada R, Corrado D, et al. Brugada Syndrome Report of the Second Consensus Conference Endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation 2005;111:659-70
3. Eckardt L, Probst V, Smits JP, Bahr ES,Wolpert C, Schimpf R, et al. Long-Term prognosis of individuals with right precordial ST-segment-elevation Brugada syndrome. Circulation 2005;111:257-63
4. ProbstV, Veltmann C, Eckardt L, Meregalli PG, Gaita F, TanHLet al. Long-Term prognosis of patients diagnosed with Brugada syndrome results from the FINGER Brugada Syndrome Registry. Circulation 2010;121:635-43
5. Paul M, Gerss J, Schulze-Bahr E, Wichter T, Vahlhaus C, Wilde A, et al. Role of programmed ventricular stimulation in patients with Brugada syndrome: A meta-Analysis of worldwide published data. Eur Heart J 2007;28:2126-33
6. Sacher F, Probst V, Iesaka Y, Jacon P, Laborderie J, Mizon-Gerard F, et al. Outcome after implantation of a cardioverter-defibrillator in patients with Brugada syndrome: A multicenter study. Circulation 2006;114:2317-24
7. Probst V, Plassard-Kerdoncuf D, Mansourati J, Mabo P, Sacher F, Fruchet Cet al. The psychological impact of implantable cardioverter defibrillator implantation on Brugada syndrome patients. Europace 2011;13:1034-9
8. Yan G, Antzelevitch C. Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST-segment elevation. Circulation 1999; 100:1660-6
9. Belhassen B, Viskin S, Fish R, Glick A, Setbon I, Eldar M. Effects of electrophysiologicguided therapy with class IA antiarrhythmic drugs on the long-Term outcome of patients with idiopathic ventricular fibrillation with or without the Brugada syndrome. J Cardiovasc Electrophysiol 1999;10:1301-12
10. Hermida JS, Denjoy I, Clerc J, Extramiana F, Jarry G, Milliez P, et al. Hydroquinidine therapy in Brugada syndrome. J Am Coll Cardiol 2004;43:1853-60
11. Belhassen B, Glick A, Viskin S. Efficacy of quinidine in high-risk patients with Brugada syndrome. Circulation 2004;110:1731-7
12. Belhassen B, Glick A, Viskin S. Excellent long-Term reproducibility of the electrophysiologic efficacy of quinidine in patients with idiopathic ventricular fibrillation and Brugada syndrome. PACE 2009;32:294-301
13. Belhassen B, Shapir I, Shoshani D, Paredes A, Miller H, Laniado S. Idiopathic ventricular fibrillation: Inducibility and beneficial effects of class I antiarrhythmic agents. Circulation 1987;75:809-16
14. Alings M, Dekker L, Sadee A, Wilde A. Quinidine induced electrocardiographic normalization in two patients with Brugada syndrome. PACE 2001; 24:1420-2
15. Ohgo T, Okamura H, Noda T, Satomi K, Suyama K, Kurita T, et al. Acute and chronic management in patients with Brugada syndrome associated with electrical storm of ventricular fibrillation. Heart Rhythm 2007;4:695-700
16. MárquezMF,BonnyA, Hernández-Castillo E,DeSisti A,Gómez-Flores J, NavaS, et al. Long-Term efficacy of low doses of quinidine on malignant arrhythmias in Brugada syndrome with an implantable cardioverter-defibrillator: A case series and literature review. Heart Rhythm 2012;9:1995-2000
17. Brugada J, Brugada R, Antzelevitch C, Towbin J, Nadanamee K, Brugada P. Long term follow-up of individuals with the electrocardiographic pattern of right bundle branch block andST-segmentelevationinprecordial leadsV1toV3. Circulation 2002;105:73-8
18. Priori S, Napolitano C, Gasparini M, Pappone C, Della Bella P. Natural history of Brugada syndrome. Circulation 2002;105:1342-7
19. Brugada J, Brugada R, Brugada P. Determinants of sudden cardiac death in individuals with the electrocardiographic pattern of Brugada syndrome and no previous cardiac arrest. Circulation 2003;108:3092-6
20. Brugada P, Brugada R, Mont L, Rivero M, Geelen P, Brugada J. Natural history of Brugada syndrome: The prognostic value of programmed electrical stimulation of the heart. J Cardiovasc Electrophysiol 2003;14:455-7
21. Priori S, GaspariniM, Napolitano C, Della Bella P, Ghidini Ottonelli A, Sassone B, et al. Risk stratification in Brugada syndrome. Results of the PRELUDE registry. J Am Coll Cardiol 2012;59:37-45
22. Viskin S, Rogowski O. Asymptomatic Brugada syndrome: A cardiac ticking timebomb? Europace 2007;9:707-10
23. Wilde AA, Viskin S. EP testing does not predict cardiac events in Brugada syndrome. Heart Rhythm 2011;8:1598-600
24. Fauchier L, Isorni M, Clementy N, Pierre B, Simeon E, Babuty D. Prognostic value of programmed ventricular stimulation in Brugada syndrome according to clinical presentation: An updated meta-Analysis of worldwide published data. Int J Cardiol 2013. (EPUB ahead of print: 3 May 2013
25. Viskin S, Antzelevitch C, Márquez MF, Belhassen B. Quinidine: A valuable medication joins the list of 'endangered species'. Europace 2007;9:1105-6
26. Viskin S, Wilde AA, Guevara-Valdivia ME, Daoulah A, Krahn A, Zipes DPet al. Quinidine, a life-saving medication for Brugada syndrome, is inaccessible in many countries. J Am Coll Cardiol 2013;23:2383-7
27. HRS/EHRA/APHRS. Expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Europace 2013. (EPUB ahead of print: 30 August 2013.